While our framework leverages T1-weighted MRI scans for Alzheimer’s disease (AD) classification, multimodal approaches integrating neuropsychological tests and laboratory biomarkers, such as tau protein levels, offer potential to enhance diagnostic precision, particularly for early-stage detection. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.